NIH begins clinical trial of live, attenuated Zika vaccine

(NIH/National Institute of Allergy and Infectious Diseases) Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases. The NIAID-sponsored trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news